The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales ...

An experimental COPD drug from AstraZeneca could prove competitive with existing treatments, and have a slice of the market ...

COPD is the third leading cause of death worldwide, excluding COVID-19. It is a progressive respiratory condition ...

Despite recent treatment advances in chronic obstructive pulmonary disease (COPD), physicians continue to report substantial unmet need, particularly among patients with severe disease and a high risk ...

A new drug shows promise in reducing the symptoms of COPD, one of the top 10 leading cause of death in the U.S., according to ...

AstraZeneca's experimental drug, tozorakimab, significantly reduces COPD exacerbations, as presented at the European Respiratory Society Congress. The drug, effective regardless of smoking status or ...

A small trial found that laughter therapy and pursed-lip breathing reduced reported breathlessness in people with COPD.

Full results from the positive Phase III OBERON and TITANIA trials showed that tozorakimab is the first biologic to demonstrate statistically significant and highly clinically meaningful efficacy in ...

Tozorakimab cut moderate/severe COPD exacerbations up to 34% in the phase 3 trials OBERON and TITANIA across smoking status ...

Add Yahoo as a preferred source to see more of our stories on Google. Jul. 1—MORGANTOWN — A new treatment for emphysema is coming to West Virginia. The Zephyr Valve, a treatment classified a medical ...

FLORENCE, Italy — Exacerbations remain one of the major unresolved challenges in the management of chronic obstructive pulmonary disease (COPD), despite the introduction of new therapies. However, ...

The goals of COPD treatment are to reduce symptoms and symptom flare-ups. "This can be done through a combination of lifestyle changes and treatment options in consultation with your doctor," says ...